L’Episcopia, Mariangela
Kelley, Julia
Patel, Dhruviben
Schmedes, Sarah
Ravishankar, Shashidahar
Menegon, Michela
Perrotti, Edvige
Nurahmed, Abduselam M.
Talha, Albadawi A.
Nour, Bakri Y.
Lucchi, Naomi
Severini, Carlo
Talundzic, Eldin
Funding for this research was provided by:
Centers for Disease Control and Prevention
Article History
Received: 21 November 2019
Accepted: 3 March 2020
First Online: 14 March 2020
Ethics approval and consent to participate
: Original ethical approval for drug resistance studies was obtained from the Ethics Committee of the Eritrean Ministry of Health (OSM 29/377/13). The present study was approved by the Office of the Associate Director of Science, Center for Global Health, Center for Disease Control and Prevention as research not involving human subjects (protocol 2017-228). In May 2017, the Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy; the Malaria Branch laboratory at the Centers for Disease Control and Prevention (CDC), Atlanta, USA and the University of Gezira, Wad Medani, Sudan agreed to work together on generating molecular data related to the original study entitled “Genetic basis of malaria drug resistance in Eritrea”. For all samples, identifying information was removed so that data cannot be linked or re-linked with identifiable human subjects.
: Not applicable.
: The authors declare that they have no competing interests.